Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs Mitomycin C in Uncontrolled Glaucoma
NCT02901236Phase 3Completed
- Sponsor
- Athens Vision Eye Institute
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in Glaucoma (2 arms), sponsored by Athens Vision Eye Institute. Primary endpoint: Intraocular Pressure at 1 year. Started Jan 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT02901236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901236.